REGN1908-1909

DRUG4 trials

Sponsors

Regeneron Pharmaceuticals

Conditions

Allergic Rhinitis Due to Cat AllergyAllergyCat AllergyMild Asthma

Phase 1

Single Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Subjects

CompletedNCT01922661

Regeneron PharmaceuticalsAllergy

Start: 2013-08-31End: 2014-05-31Updated: 2014-06-10

Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Participants

CompletedNCT02127801

Regeneron PharmaceuticalsAllergy

Start: 2014-10-31End: 2015-12-31Updated: 2020-12-16

Phase 2

Study in Cat-Allergic Patients With Asthma to Evaluate the Efficacy of a Single Dose of REGN1908-1909 to Reduce Bronchoconstriction Upon Cat Allergen Challenge

CompletedNCT03838731

Regeneron PharmaceuticalsCat Allergy, Mild Asthma

Start: 2019-02-12End: 2020-04-06Updated: 2021-07-01

Phase 3

A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat

TerminatedNCT04981717

Regeneron PharmaceuticalsAllergic Rhinitis Due to Cat Allergy

Start: 2021-07-30End: 2023-04-24Updated: 2024-06-11

Related Papers

REGN1908/1909 prevented cat allergen-induced early asthmatic responses in an environmental exposure unit.

2022-08-0426 citations

Passive Prophylactic Administration with a Single Dose of Anti–Fel d 1 Monoclonal Antibodies REGN1908–1909 in Cat Allergen–induced Allergic Rhinitis: A Randomized, Double-Blind, Placebo-controlled Clinical Trial

American Journal of Respiratory and Critical Care Medicine2021-03-0268 citations